Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Acumen Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $78.6 million which is expected to fund operations into early 2027. The company announced it expects to report topline results from its ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer’s disease in November 2026.
Term
Q3 2026
“In the third quarter, we continued readying for the readout from our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, and today I’m pleased to announce that we expect to report topline results in November 2026. We remain encouraged by the potential for sabirnetug to become a treatment of choice, with a differentiated benefit-risk profile driven by its unique attributes as an anti-AβO IgG2 monoclonal antibody.”
Daniel O’Connell, Chief Executive Officer of Acumen
Range Resources Corporation has entered into a definitive agreement to be acquired by EQT Corporation in an all-stock transaction, creating a combined natural gas company with a pro forma enterprise value exceeding $50 billion. Range stockholders will receive 0.987 shares of EQT common stock for each Range share, resulting in Range stockholders owning approximately 27% of the combined entity. The merger aims to create the leading vertically integrated natural gas producer in North America with over 30 years of inventory and significant cost synergies.
Counterparty
EQT Corporation
“This transaction brings together two of the highest-quality, longest-duration asset bases in North America and creates a company uniquely positioned for the next era of natural gas. As the lowest-cost natural gas producer in the industry, supported by multiple decades of high-quality inventory, the combined company will offer exceptional resilience through commodity cycles while maintaining significant upside to strengthening natural gas fundamentals.”
Toby Z. Rice, EQT President and CEO
“This combination of two highly successful operators with decades of inventory creates opportunities to build long-term value neither could fully realize independently.”
United States Antimony Corp announced the completion of a new Technical Report Summary (TRS) for its Nolan Creek Property in Alaska, which is prospective for antimony and gold. The report, prepared in accordance with SEC S-K 1300 requirements, provides an initial assessment and estimation of mineral resources for the property acquired by the company in early 2026.
Verizon reported record-breaking Q3 2026 results with 406,000 postpaid phone net additions and its best quarterly net account growth in over a decade. The company raised its full-year guidance for the third consecutive quarter and announced a landmark $2 billion AI infrastructure partnership with AWS.
Term
Q3 2026
“Verizon delivered another record-breaking quarter. One year into our transformation, Verizon is fundamentally stronger — operationally, financially, and competitively. By prioritizing customer-first offerings like Simplicity and our expanded loyalty program over heavy subsidies, we are winning loyal, high-value customers while expanding margins, reducing churn, and generating strong sustained cash flow. At the same time, technology leaders are choosing our fiber network to power the next generation of AI infrastructure. We are continuing to raise the bar and we are only one year into a multi-year growth story.”
HBT Financial reported strong third quarter 2026 net income of $31.4 million, or $0.86 per diluted share, driven by a net interest margin expansion to 4.35% and strong asset quality. The company noted that integration planning for its pending acquisition of Tri-County Financial Group is progressing well with an expected close in early Q1 2027.
Term
Q3 2026
“Our third quarter results were very strong with adjusted net income of $31.4 million, or $0.86 per diluted share, an increase of 10.1% over the prior quarter. Profitability also remained strong with adjusted ROAA of 1.85% and adjusted ROATCE of 19.29%.”
J. Lance Carter, President and Chief Executive Officer
“Integration planning for the acquisition of Tri-County Financial Group, Inc. is progressing well, and we anticipate this transaction closing early in the first quarter of 2027, subject to their stockholder approval and regulatory approvals.”
J. Lance Carter, President and Chief Executive Officer
Getty Images Holdings and several subsidiaries filed voluntary petitions for Chapter 11 bankruptcy protection in the District of Delaware to implement a prepackaged plan of reorganization. In connection with the filing, the company entered into a $143 million debtor-in-possession (DIP) credit agreement with Cantor Fitzgerald Securities to fund operations during the restructuring process. The DIP facility includes an initial $85 million draw to cover legal costs, working capital, and general corporate purposes.
Jamere Jackson has resigned as Chief Financial Officer of AutoZone, effective November 25, 2026, to become the CFO of FedEx Corporation. The company has initiated an external search for a successor, and Vice President and Controller J. Scott Murphy will serve as the interim principal financial officer.
Zeo ScientifiX and Pluri Inc. entered into a definitive strategic agreement to expand their U.S. manufacturing and commercialization platform for regenerative medicine and aesthetics. The transaction involves a share exchange that will result in Pluri owning 50% of ZEO, combining Pluri's 3D cell-expansion technology with ZEO's biologics manufacturing and physician sales network.
Lakeland Financial Corporation filed its 3Q 2026 investor presentation to be used in upcoming meetings with investors and analysts. The presentation highlights the company's long-term shareholder value creation, including a 20-year tangible book value per share CAGR of over 8% and a return on equity exceeding 13%.
Lakeland Financial reported record third quarter net income of $28.9 million, up 9% year-over-year, driven by 8% loan growth and net interest margin expansion. Diluted earnings per share reached a record $1.14, an 11% increase from the prior year period.
Term
Q3 2026
“Strong loan growth and healthy net interest margin expansion were reflected in the quality of our earnings performance in the quarter. Clearly, the resulting record net income reflects the efforts of the entire Lake City Bank team as we continue to grow our market share in every market we serve.”
Ovintiv Signs $890M M&A Deal with Logan Energy Corp.
Ovintiv Inc. has entered into a definitive agreement to acquire Logan Energy Corp. in an all-cash transaction valued at approximately $890 million (C$1.26 billion), including the assumption of net debt. The acquisition adds approximately 266,000 net acres and 420 net drilling locations in the oil-rich window of the Montney play, increasing Ovintiv's scale and inventory in the region.
Value
$890M
Counterparty
Logan Energy Corp.
“This bolt-on transaction delivers value for our shareholders by adding high margin oil and condensate production and infrastructure, utilizing our operational advantage to drive significant synergies, and adding to our already deep drilling inventory and future growth optionality. The Logan assets have demonstrated leading oil productivity performance and will immediately compete for capital alongside the rest of our portfolio.”
Easterly Government Properties reported Q3 2026 net income of $5.7 million and Core FFO of $38.0 million, or $0.78 per share. The REIT maintained a 98% leased portfolio of 106 operating properties primarily leased to U.S. Government agencies and completed a laboratory facility in Fort Myers, Florida subsequent to quarter end.
Term
Q3 2026
“Despite continued volatility in the broader market, Easterly’s government-focused portfolio continues to provide stability and durability. Our third quarter results reflect disciplined execution across the business and the strength of the platform we have built.”
News Corp provided a daily update on its existing $1 billion stock repurchase program as required by Australian Securities Exchange (ASX) rules. The filing includes notifications of recent buy-back transactions for the company's Nasdaq-listed Class A and Class B common stock.
Vertiv Holdings M&A Deal with King Environmental Services Ltd.
Vertiv Holdings Co. has completed the acquisition of King Environmental Services Ltd. (KES), a Europe-based provider of fluid management and load-testing services for liquid-cooled data centers. The deal expands Vertiv's thermal management capabilities into the EMEA region, building on its previous acquisition of PurgeRite to support high-density and AI-driven computing environments.
Counterparty
King Environmental Services Ltd.
“As computing density increases, the performance of cooling infrastructure depends not only on engineering and system design but on execution in the field. KES builds on the Vertiv fluid management foundation, extending our specialized expertise and disciplined execution into EMEA as customers deploy increasingly complex infrastructure at scale.”
Giordano Albertazzi, Chief Executive Officer of Vertiv
Renee Swan resigned as Senior Vice President and Chief People Officer of Atmus Filtration Technologies, effective November 11, 2026, to pursue other opportunities. Laura Heltebran, the company's Chief Legal Officer, will assume the role of Chief People Officer on an interim basis until a permanent replacement is named.
KKR & Co. Inc. has appointed Brian J. Lee, the former Chief Risk Officer of Goldman Sachs, to its Board of Directors, effective October 26, 2026. Mr. Lee will also serve on the Board's Audit and Risk Committees and will participate in the company's standard non-executive director compensation program. His appointment increases the total number of directors to twelve, eight of whom are independent.
Braemar Hotels & Resorts announced its slate of eight director nominees for election at the upcoming 2026 Annual Meeting of Stockholders. The slate includes seven new independent nominees and current CEO Richard J. Stockton, representing a significant board refresh for the company.
Climb Bio announced initial Phase 2 data from its PrisMN trial evaluating budoprutug in patients with primary membranous nephropathy (pMN), showing a 70% mean reduction in PLA2R antibody levels at Week 12 in the 200 mg cohort. Initial data from the 600 mg cohort indicated deeper B-cell depletion and greater drug exposure, supporting the ongoing evaluation of higher doses. The company also reported a case study in minimal change disease (MCD) where a patient achieved a three-year steroid-free remission following treatment.
EQT Signs $50B M&A Deal with Range Resources Corporation
EQT Corporation has entered into a definitive agreement to acquire Range Resources Corporation in an all-stock transaction, creating a combined natural gas company with a pro forma enterprise value of over $50 billion. Range stockholders will receive 0.987 shares of EQT common stock for each share held, resulting in EQT and Range shareholders owning approximately 73% and 27% of the combined company, respectively. The deal aims to create the largest vertically integrated natural gas producer in the U.S. with significant inventory depth and expected annual synergies of $325 million.
Value
$50B
Counterparty
Range Resources Corporation
“This transaction brings together two of the highest-quality, longest-duration asset bases in North America and creates a company uniquely positioned for the next era of natural gas. As the lowest-cost natural gas producer in the industry, supported by multiple decades of high-quality inventory, the combined company will offer exceptional resilience through commodity cycles while maintaining significant upside to strengthening natural gas fundamentals.”
Amanat Acquisition Signs $377M M&A Deal with Corxel Pharmaceuticals, Inc.
Amanat Acquisition Corp (AMAN) has entered into a definitive business combination agreement with Corxel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on oral obesity therapies. The transaction is expected to provide approximately $377 million in gross proceeds, including a $300 million PIPE investment from institutional investors. Upon closing, expected in the first half of 2027, the combined company will focus on advancing Corxel's oral GLP-1 receptor agonist, CX11, into Phase 3 clinical trials.
Atlantis Glory Inc. remains a dormant shell company with no revenue and no assets as of September 30, 2026. The company reported a net loss of $24,377 for the nine months ended September 30, 2026, primarily due to general and administrative expenses, and is currently seeking a reverse merger.
Game Your Game Inc. appointed Wendy Loundermon as Chief Financial Officer, effective October 16, 2026, succeeding Dominic Poole. Ms. Loundermon previously served as CFO of Grafiti LLC and XTI Aerospace, Inc., while Mr. Poole will remain with the company as Vice President of Finance. Additionally, the company amended warrants held by Streeterville Capital, LLC to reduce their exercise price to $1.00 per share.
Artificial Intelligence Technology Solutions Business Update
Artificial Intelligence Technology Solutions Inc. (AITX) defined four internal operating milestones to measure its progress toward breakeven, with the first milestone (monthly operating cash breakeven) targeted for January 2027. The company is implementing a cost-reduction program aimed at saving over $350,000 per month by February 2027, which includes a reduction in force of 24 positions and cuts in marketing and cloud expenses.
HyOrc Deal Termination with ONENERGY GREENPOWER EAD and ON ENERGY EOOD
HyOrc Corporation received a notice from OnEnergy purporting to terminate their March 2026 agreement regarding a waste-to-methanol project in Bulgaria following a failed joint grant application. HyOrc is formally disputing the validity of the termination, claiming the contractual conditions for such an action have not been met, and has reserved its intellectual property rights.
Oaktree Acquisition Corp. III Life Sciences Other 8-K Filing
Oaktree Acquisition Corp. III Life Sciences held an extraordinary general meeting where shareholders approved an amendment to extend the deadline for completing an initial business combination from October 25, 2026, to as late as May 25, 2027. Additionally, the company's Sponsor converted 4,798,758 Class B ordinary shares into Class A ordinary shares on a one-for-one basis.
Stratum Holdings Corp. completed an additional closing under a securities purchase agreement with an institutional investor, issuing 200 shares of Series E Convertible Preferred Stock. The transaction generated gross proceeds of $200,000 at a stated value of $1,000 per share. This follows an initial issuance of 200 shares on September 15, 2026.
The New York Stock Exchange (NYSE) has commenced proceedings to delist Elme Communities' common shares and immediately suspended trading due to abnormally low selling price levels. The company does not intend to appeal the decision as it is already executing a previously approved Plan of Sale and Liquidation. Elme anticipates its shares will begin trading over-the-counter (OTC) under the symbol 'ELMES' on October 26, 2026.
Phathom Pharmaceuticals announced that the FDA has opened a public docket to solicit comments regarding legal challenges brought by BDR Pharmaceuticals against the FDA's decision to grant VOQUEZNA 10 years of New Chemical Entity (NCE) exclusivity. The litigation challenges the exclusivity period that currently protects VOQUEZNA through May 2032, and a second potential generic filer, Saba Ilac Sanayii Ve Ticaret AS, has also indicated intent to join the legal challenge.
ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted antibody-drug conjugate ARR-217 in patients with gastrointestinal cancers, reporting a 44.8% objective response rate at the 6mg/kg dose in late-line colorectal cancer patients. The study, conducted in partnership with Lepu Biopharma, showed a manageable safety profile and has advanced into Phase 1b dose optimization with further data expected in 2027.
Counterparty
Lepu Biopharma Co., Ltd.
“These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy.”
Bing Yao, Ph.D., Chief Executive Officer of ArriVent
“We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study.”
Bing Yao, Ph.D., Chief Executive Officer of ArriVent